Effects of prostaglandin analogues on aqueous humor outflow pathways

Journal of Ocular Pharmacology and Therapeutics

Volumn 30, Issue 2-3, 2014, Pages 102-109

  Winkler, Nelson S ^a   Fautsch, Michael P ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 FLUORO 9,15 DIHYDROXY 15 (2 INDANYL) 16,17,18,19,20 PENTANORPROSTA 5,13 DIENOIC ACID; ANTIHYPERTENSIVE AGENT; BIMATOPROST; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; LATANOPROST; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN RECEPTOR; TAFLUPROST; TIMOLOL MALEATE; TRAVOPROST; UNCLASSIFIED DRUG;

AQUEOUS HUMOR FORMATION; AQUEOUS HUMOR OUTFLOW; BLINDNESS; CELL ADHESION; CELL MIGRATION; CELL NUCLEUS MEMBRANE; CELL SURVIVAL; DISEASE COURSE; DRUG EFFECT; DRUG IDENTIFICATION; EXTRACELLULAR MATRIX; GLAUCOMA; HUMAN; IN VITRO STUDY; INTRAOCULAR PRESSURE; NONHUMAN; OPEN ANGLE GLAUCOMA; REVIEW; TRABECULAR MESHWORK; ANIMAL; AQUEOUS HUMOR; DRUG DESIGN; DRUG EFFECTS; METABOLISM; RISK FACTOR;

ANIMALS; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; DRUG DESIGN; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; PROSTAGLANDINS, SYNTHETIC; RISK FACTORS;

EID: 84898756412     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2013.0179     Document Type: Review

References (104)

1. Toris, C.B., Yablonski, M.E., Wang, Y.-L., and Camras, C.B. Aqueous humor dynamics in the aging human eye. Am. J. Ophthal. 127:407-412, 1999.
2. Overby, D.R., Stamer, W.D., and Johnson, M. The changing paradigm of outflow resistance generation: towards synergistic models of the JCT and inner wall endothelium. Exp. Eye Res. 88:656-670, 2009.
3. Brubaker, R.F. Targeting outflow facility in glaucoma management. Surv. Ophthalmol. 48 Suppl 1:S17-S20, 2003.
4. Liu, J.H., Zhang, X., Kripke, D.F., and Weinreb, R.N. Twenty-four-hour intraocular pressure pattern associated with early glaucomatous changes. Invest. Ophthalmol. Vis. Sci. 44:1586-1590, 2003.
5. Stamer, W.D., and Acott, T.S. Current understanding of conventional outflow dysfunction in glaucoma. Curr. Opin. Ophthalmol. 23:135-143, 2012.
6. Colina-Chourio, J.A., Godoy-Godoy, N., and Avila-Hernandez, R.M. Role of prostaglandins in hypertension. J. Hum. Hypertens. 14 Suppl 1:S16-S19, 2000.
7. Hata, A.N., and Breyer, R.M. Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol. Ther. 103:147-166, 2004.
8. Camras, C.B., Bito, L.Z., and Eakins, K.E. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits. Invest. Ophthalmol. Vis. Sci. 16:1125-1134, 1977.
9. Aptel, F., Cucherat, M., and Denis, P. Efficacy and tolerability of prostaglandin analogs: a meta-analysis of randomized controlled clinical trials. J. Glaucoma. 17:667-673, 2008.
10. Choplin, N., Bernstein, P., Batoosingh, A.L., and Whitcup, S.M. A randomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv. Ophthalmol. 49 Suppl 1:S19-S25, 2004.
11. Costagliola, C., Del Prete, A., Verolino, M., Antinozzi, P., Fusco, R., Parmeggiani, F., and Mastropasqua, L. Effect of 0.005% latanoprost once daily on intraocular pressure in glaucomatous patients not adequately controlled by beta-blockers twice daily: a 3-year follow-up. Experience and incidence of side effects in a prospective study on 76 patients. Graefes Arch. Clin. Exp. Ophthalmol. 240:379-386, 2002.
12. Brubaker, R.F. Mechanism of action of bimatoprost (Lumigan). Surv. Ophthalmol. 45 Suppl 4:S347-S351, 2001.
13. Cheng, J.W., Li, Y., and Wei, R.L. Systematic review of intraocular pressure-lowering effects of adjunctive medications added to latanoprost. Ophthalmic Res. 42:99-105, 2009.
14. Tabet, R., Stewart, W.C., Feldman, R., and Konstas, A.G. A review of additivity to prostaglandin analogs: fixed and unfixed combinations. Surv. Ophthalmol. 53 Suppl 1:S85-S92, 2008.
15. Woodward, D.F., and Chen, J. Fixed-combination and emerging glaucoma therapies. Expert Opin. Emerg. Drugs. 12:313-327, 2007.
16. Eisenberg, D. Latanoprost versus bimatoprost. Ophthalmology. 110:1861-1862, 2003; author reply 1862.
17. Gandolfi, S.A., and Cimino, L. Effect of bimatoprost on patients with primary open-angle glaucoma or ocular hypertension who are nonresponders to latanoprost. Ophthalmology. 110:609-614, 2003.
18. Kammer, J.A., Katzman, B., Ackerman, S.L., and Hollander, D.A. Efficacy and tolerability of bimatoprost versus travoprost in patients previously on latanoprost: a 3-month, randomised, masked-evaluator, multicentre study. Br. J. Ophthalmol. 94:74-79, 2010.
19. Cheng, J.W., and Wei, R.L. Meta-analysis of 13 randomized controlled trials comparing bimatoprost with latanoprost in patients with elevated intraocular pressure. Clin. Ther. 30:622-632, 2008.
20. Denis, P., Lafuma, A., Khoshnood, B., Mimaud, V., and Berdeaux, G. A meta-analysis of topical prostaglandin analogues intra-ocular pressure lowering in glaucoma therapy. Curr. Med. Res. Opin. 23:601-608, 2007.
21. Gandolfi, S., Simmons, S.T., Sturm, R., Chen, K., and VanDenburgh, A.M. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv. Ther. 18:110-121, 2001.
22. Holmstrom, S., Buchholz, P., Walt, J., Wickstrom, J., and Aagren, M. Analytic review of bimatoprost, latanoprost and travoprost in primary open angle glaucoma. Curr. Med. Res. Opin. 21:1875-1883, 2005.
23. Simmons, S.T., Dirks, M.S., and Noecker, R.J. Bimatoprost versus latanoprost in lowering intraocular pressure in glaucoma and ocular hypertension: results from parallelgroup comparison trials. Adv. Ther. 21:247-262, 2004.
24. Woodward, D.F., Carling, R.W., Cornell, C.L., Fliri, H.G., Martos, J.L., Pettit, S.N., Liang, Y., and Wang, J.W. The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products. Pharmacol. Ther. 120:71-80, 2008.
25. Schlotzer-Schrehardt, U., Zenkel, M., and Nusing, R.M. Expression and localization of FP and EP prostanoid receptor subtypes in human ocular tissues. Invest. Ophthalmol. Vis Sci. 43:1475-1487, 2002.
26. Sharif, N.A., Kelly, C.R., Crider, J.Y., Williams, G.W., and Xu, S.X. Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells. J. Ocul. Pharmacol. Ther. 19:501-515, 2003.
27. Swymer, C., and Neville, M.W. Tafluprost: the first preservative-free prostaglandin to treat open-angle glaucoma and ocular hypertension. Ann. Pharmacother. 46:1506-1510, 2012.
28. Abramovitz, M., Adam, M., Boie, Y., Carriere, M., Denis, D., Godbout, C., Lamontagne, S., Rochette, C., Sawyer, N., Tremblay, N.M., Belley, M., Gallant, M., Dufresne, C., Gareau, Y., Ruel, R., Juteau, H., Labelle, M., Ouimet, N., and Metters, K.M. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim. Biophys. Acta. 1483:285-293, 2000.
29. Liang, Y., Woodward, D.F., Guzman, V.M., Li, C., Scott, D.F., Wang, J.W., Wheeler, L.A., Garst, M.E., Landsverk, K., Sachs, G., Krauss, A.H., Cornell, C., Martos, J., Pettit, S., and Fliri, H. Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes. Br. J. Pharmacol. 154:1079-1093, 2008.
30. Sharif, N.A., and Klimko, P. Update and commentary on the pro-drug bimatoprost and a putative 'prostamide receptor'. Expert Rev. Ophthalmol. 4:477-489, 2009.
31. Patil, A.J., Vajaranant, T.S., and Edward, D.P. Bimatoprost-a review. Expert Opin. Pharmacother. 10:2759-2768, 2009.
32. Anthony, T.L., Pierce, K.L., Stamer, W.D., and Regan, J.W. Prostaglandin F2 alpha receptors in the human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 39:315-321, 1998.
33. Kamphuis, W., Schneemann, A., van Beek, L.M., Smit, A.B., Hoyng, P.F., and Koya, E. Prostanoid receptor gene expression profile in human trabecular meshwork: a quantitative real-time PCR approach. Invest. Ophthalmol. Vis. Sci. 42:3209-3215, 2001.
34. Thieme, H., Schimmat, C., Munzer, G., Boxberger, M., Fromm, M., Pfeiffer, N., and Rosenthal, R. Endothelin antagonism: effects of FP receptor agonists prostaglandin F2alpha and fluprostenol on trabecular meshwork contractility. Invest. Ophthalmol. Vis. Sci. 47:938-945, 2006.
35. Wang, J.W., Woodward, D.F., and Stamer, W.D. Differential effects of prostaglandin E2-sensitive receptors on contractility of human ocular cells that regulate conventional outflow. Invest. Ophthalmol. Vis. Sci. 54:4782-4790, 2013.
36. Davis, T.L., and Sharif, N.A. Quantitative autoradiographic visualization and pharmacology of FP-prostaglandin receptors in human eyes using the novel phosphorimaging technology. J. Ocul. Pharmacol. Ther. 15:323-336, 1999.
37. Sharif, N.A., Davis, T.L., and Williams, G.W. [3H]AL-5848 ([3H]9beta-( + )-Fluprostenol). Carboxylic acid of travoprost (AL-6221), a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J. Pharm. Pharmacol. 51:685-694, 1999.
38. Sharif, N.A., Williams, G.W., and Davis, T.L. Pharmacology and autoradiography of human DP prostanoid receptors using [(3)H]-BWA868C, a DP receptor-selective antagonist radioligand. Br. J. Pharmacol. 131:1025-1038, 2000.
39. Ota, T., Aihara, M., Narumiya, S., and Araie, M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. 46:4159-4163, 2005.
40. Griffin, B.W., Klimko, P., Crider, J.Y., and Sharif, N.A. AL-8810: a novel prostaglandin F2 alpha analog with selective antagonist effects at the prostaglandin F2 alpha (FP) receptor. J. Pharmacol. Exp. Ther. 290:1278-1284, 1999.
41. Sharif, N.A., Kelly, C.R., and Crider, J.Y. Human trabecular meshwork cell responses induced by bimatoprost, travoprost, unoprostone, and other FP prostaglandin receptor agonist analogues. Invest. Ophthalmol. Vis. Sci. 44:715-721, 2003.
42. Ota, T., Aihara, M., Saeki, T., Narumiya, S., and Araie, M. The effects of prostaglandin analogues on prostanoid EP1, EP2, and EP3 receptor-deficient mice. Invest. Ophthalmol. Vis. Sci. 47:3395-3399, 2006.
43. Nilsson, S.F., Drecoll, E., Lutjen-Drecoll, E., Toris, C.B., Krauss, A.H., Kharlamb, A., Nieves, A., Guerra, T., and Woodward, D.F. The prostanoid EP2 receptor agonist butaprost increases uveoscleral outflow in the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. 47:4042-4049, 2006.
44. Woodward, D.F., Nilsson, S.F., Toris, C.B., Kharlamb, A.B., Nieves, A.L., and Krauss, A.H. Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow. Invest. Ophthalmol. Vis. Sci. 50:3320-3328, 2009.
45. Alm, A., and Villumsen, J. PhXA34, a new potent ocular hypotensive drug. A study on dose-response relationship and on aqueous humor dynamics in healthy volunteers. Arch. Ophthalmol. 109:1564-1568, 1991.
46. Kerstetter, J.R., Brubaker, R.F., Wilson, S.E., and Kullerstrand, L.J. Prostaglandin F2 alpha-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow. Am. J. Ophthalmol. 105:30-34, 1988.
47. Lim, K.S., Nau, C.B., O'Byrne, M.M., Hodge, D.O., Toris, C.B., McLaren, J.W., and Johnson, D.H. Mechanism of action of bimatoprost, latanoprost, and travoprost in healthy subjects. A crossover study. Ophthalmology. 115:790-795.e794, 2008.
48. Linden, C., and Alm, A. Prostaglandin analogues in the treatment of glaucoma. Drugs Aging. 14:387-398, 1999.
49. Toris, C.B., Camras, C.B., and Yablonski, M.E. Effects of PhXA41, a new prostaglandin F2 alpha analog, on aqueous humor dynamics in human eyes. Ophthalmology. 100:1297-1304, 1993.
50. Ziai, N., Dolan, J.W., Kacere, R.D., and Brubaker, R.F. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch. Ophthalmol. 111:1351-1358, 1993.
51. Toris, C.B., Gabelt, B.T., and Kaufman, P.L. Update on the mechanism of action of topical prostaglandins for intraocular pressure reduction. Surv. Ophthalmol. 53 Suppl 1:S107-S120, 2008.
52. Alm, A., and Nilsson, S.F. Uveoscleral outflow-a review. Exp. Eye Res. 88:760-768. 2009.
53. Poyer, J.F., Millar, C., and Kaufman, P.L. Prostaglandin F2 alpha effects on isolated rhesus monkey ciliary muscle. Invest. Ophthalmol. Vis. Sci. 36:2461-2465, 1995.
54. Stamer, W.D., Piwnica, D., Jolas, T., Carling, R.W., Cornell, C.L., Fliri, H., Martos, J., Pettit, S.N., Wang, J.W., and Woodward, D.F. Cellular basis for bimatoprost effects on human conventional outflow. Invest. Ophthalmol. Vis. Sci. 51:5176-5181, 2010.
55. Schachtschabel, U., Lindsey, J.D., and Weinreb, R.N. The mechanism of action of prostaglandins on uveoscleral outflow. Curr. Opin. Ophthalmol. 11:112-115, 2000.
56. Lindsey, J.D., Kashiwagi, K., Boyle, D., Kashiwagi, F., Firestein, G.S., and Weinreb, R.N. Prostaglandins increase proMMP-1 and proMMP-3 secretion by human ciliary smooth muscle cells. Curr. Eye Res. 15:869-875, 1996.
57. Lindsey, J.D., Kashiwagi, K., Kashiwagi, F., and Weinreb, R.N. Prostaglandin action on ciliary smooth muscle extracellular matrix metabolism: implications for uveoscleral outflow. Surv. Ophthalmol. 41 Suppl 2:S53-S59, 1997.
58. Lindsey, J.D., Kashiwagi, K., Kashiwagi, F., and Weinreb, R.N. Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro. Invest. Ophthalmol. Vis. Sci. 38:2214-2223, 1997.
59. Lindsey, J.D., To, H.D., and Weinreb, R.N. Induction of c-fos by prostaglandin F2 alpha in human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 35:242-250, 1994.
60. Sagara, T., Gaton, D.D., Lindsey, J.D., Gabelt, B.T., Kaufman, P.L., and Weinreb, R.N. Reduction of collagen type I in the ciliary muscle of inflamed monkey eyes. Invest. Ophthalmol. Vis. Sci. 40:2568-2576, 1999.
61. Weinreb, R.N., and Lindsey, J.D. Metalloproteinase gene transcription in human ciliary muscle cells with latanoprost. Invest. Ophthalmol. Vis. Sci. 43:716-722, 2002.
62. Oh, D.J., Martin, J.L., Williams, A.J., Peck, R.E., Pokorny, C., Russell, P., Birk, D.E., and Rhee, D.J. Analysis of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human ciliary body after latanoprost. Invest. Ophthalmol. Vis. Sci. 47:953-963, 2006.
63. Baker, A.H., Edwards, D.R., and Murphy, G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J. Cell Sci. 115:3719-3727, 2002.
64. Nagase, H., Visse, R., and Murphy, G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 69:562-573, 2006.
65. Nagase, H., and Woessner Jr., J.F. Matrix metalloproteinases. J. Biol. Chem. 274:21491-21494, 1999.
66. Van den Steen, P.E., Dubois, B., Nelissen, I., Rudd, P.M., Dwek, R.A., and Opdenakker, G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37:375-536, 2002.
67. Hinz, B., Rosch, S., Ramer, R., Tamm, E.R., and Brune, K. Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. FASEB J. 19:1929-1931, 2005.
68. Oh, D.J., Martin, J.L., Williams, A.J., Russell, P., Birk, D.E., and Rhee, D.J. Effect of latanoprost on the expression of matrix metalloproteinases and their tissue inhibitors in human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 47:3887-3895, 2006.
69. Weinreb, R.N., Kashiwagi, K., Kashiwagi, F., Tsukahara, S., and Lindsey, J.D. Prostaglandins increase matrix metalloproteinase release from human ciliary smooth muscle cells. Invest. Ophthalmol. Vis. Sci. 38:2772-2780, 1997.
70. Lutjen-Drecoll, E., and Tamm, E. Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2 alpha. Exp. Eye Res. 47:761-769, 1988.
71. Bahler, C.K., Howell, K.G., Hann, C.R., Fautsch, M.P., and Johnson, D.H. Prostaglandins increase trabecular meshwork outflow facility in cultured human anterior segments. Am. J. Ophthalmol. 145:114-119, 2008.
72. Wan, Z., Woodward, D.F., Cornell, C.L., Fliri, H.G., Martos, J.L., Pettit, S.N., Wang, J.W., Kharlamb, A.B., Wheeler, L.A., Garst, M.E., Landsverk, K.J., Struble, C.S., and Stamer, W.D. Bimatoprost, prostamide activity, and conventional drainage. Investig. Ophthal. Vis. Sci. 48:4107-4115, 2007.
73. Bill, A., Lutjen-Drecoll, E., and Svedbergh, B. Effects of intracameral Na2EDTA and EGTA on aqueous outflow routes in the monkey eye. Invest. Ophthalmol. Vis. Sci. 19:492-504, 1980.
74. Svedbergh, B., Lutjen-Drecoll, E., Ober, M., and Kaufman, P.L. Cytochalasin B-induced structural changes in the anterior ocular segment of the cynomolgus monkey. Invest. Ophthalmol. Vis. Sci. 17:718-734, 1978.
75. Richter, M., Krauss, A.H., Woodward, D.F., and Lutjen-Drecoll, E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest. Ophthalmol. Vis. Sci. 44:4419-4426, 2003.
76. Pang, I.H., Hellberg, P.E., Fleenor, D.L., Jacobson, N., and Clark, A.F. Expression of matrix metalloproteinases and their inhibitors in human trabecular meshwork cells. Investig. Ophthal. Vis. Sci. 44:3485-3493, 2003.
77. Parshley, D.E., Bradley, J.M., Samples, J.R., Van Buskirk, E.M., and Acott, T.S. Early changes in matrix metalloproteinases and inhibitors after in vitro laser treatment to the trabecular meshwork. Curr. Eye Res. 14:537-544, 1995.
78. Bradley, J.M., Vranka, J., Colvis, C.M., Conger, D.M., Alexander, J.P., Fisk, A.S., Samples, J.R., and Acott, T.S. Effect of matrix metalloproteinases activity on outflow in perfused human organ culture. Invest. Ophthalmol. Vis. Sci. 39:2649-2658, 1998.
79. Arai, M., Anderson, D., Kurdi, Y., Annis-Freeman, B., Shields, K., Collins-Racie, L.A., Corcoran, C., DiBlasio-Smith, E., Pittman, D.D., Dorner, A.J., Morris, E., and LaVallie, E.R. Effect of adenovirus-mediated overexpression of bovine ADAMTS-4 and human ADAMTS-5 in primary bovine articular chondrocyte pellet culture system. Osteoarthritis Cartilage. 12:599-613, 2004.
80. Ishiguro, N., and Kojima, T. [Role of aggrecanase and MMP in cartilage degradation]. Clin. Calcium. 14:38-44, 2004.
81. Aihara, M., Lindsey, J.D., and Weinreb, R.N. Reduction of intraocular pressure in mouse eyes treated with latanoprost. Invest. Ophthalmol. Vis. Sci. 43:146-150, 2002.
82. Costagliola, C., dell'Omo, R., Romano, M.R., Rinaldi, M., Zeppa, L., and Parmeggiani, F. Pharmacotherapy of in-traocular pressure-part II. Carbonic anhydrase inhibitors, prostaglandin analogues and prostamides. Expert Opin. Pharmacother. 10:2859-2870, 2009.
83. Hotehama, Y., and Mishima, H.K. Clinical efficacy of PhXA34 and PhXA41, two novel prostaglandin F2 alphaisopropyl ester analogues for glaucoma treatment. Jpn. J. Ophthalmol. 37:259-269, 1993.
84. Larsson, L.I., Mishima, H.K., Takamatsu, M., Orzalesi, N., and Rossetti, L. The effect of latanoprost on circadian intraocular pressure. Surv. Ophthalmol. 47 Suppl 1:S90-S96, 2002.
85. Nguyen, Q.H. The role of prostaglandin analogues in the treatment of glaucoma in the 21st century. Int. Ophthalmol. Clin. 44:15-27, 2004.
86. Abramovitz, M., Boie, Y., Nguyen, T., Rushmore, T.H., Bayne, M.A., Metters, K.M., Slipetz, D.M., and Grygorczyk, R. Cloning and expression of a cDNA for the human prostanoid FP receptor. J. Biol. Chem. 269:2632-2636, 1994.
87. Sugimoto, Y., Hasumoto, K., Namba, T., Irie, A., Katsuyama, M., Negishi, M., Kakizuka, A., Narumiya, S., and Ichikawa, A. Cloning and expression of a cDNA for mouse prostaglandin F receptor. J. Biol. Chem. 269:1356-1360, 1994.
88. Watanabe, T., Nakao, A., Emerling, D., Hashimoto, Y., Tsukamoto, K., Horie, Y., Kinoshita, M., and Kurokawa, K. Prostaglandin F2 alpha enhances tyrosine phosphorylation and DNA synthesis through phospholipase C-coupled receptor via Ca(2 + )-dependent intracellular pathway in NIH-3T3 cells. J. Biol. Chem. 269:17619-17625, 1994.
89. He, Y., Ge, J., and Tombran-Tink, J. Mitochondrial defects and dysfunction in calcium regulation in glaucomatous trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 49:4912-4922, 2008.
90. Matsuo, T., and Matsuo, N. Intracellular calcium response to hydraulic pressure in human trabecular cells. Br. J. Ophthalmol. 80:561-566, 1996.
91. Dismuke, W.M., and Ellis, D.Z. Activation of the BKCa channel increases outflow facility and decreases trabecular meshwork cell volume. J. Ocul. Pharmacol. Ther. 4:309-313, 2009.
92. Ellis, D.Z., Sharif, N.A., and Dismuke, W.M. Endogenous regulation of human Schlemm's canal cell volume by nitric oxide signaling. Invest. Ophthalmol. Vis. Sci. 51:5817-5824, 2010.
93. Bos, C.L., Richel, D.J., Ritsema, T., Peppelenbosch, M.P., and Versteeg, H.H. Prostanoids and prostanoid receptors in signal transduction. Int. J. Biochem. Cell Biol. 36:1187-1205, 2004.
94. Pierce, K.L., Fujino, H., Srinivasan, D., and Regan, J.W. Activation of FP prostanoid receptor isoforms leads to Rho-mediated changes in cell morphology and in the cell cytoskeleton. J. Biol. Chem. 274:35944-35949, 1999.
95. Baarsma, H.A., Konigshoff, M., and Gosens, R. The WNT signaling pathway from ligand secretion to gene transcription: molecular mechanisms and pharmacological targets. Pharmacol. Ther. 138:66-83, 2013.
96. Sales, K.J., Milne, S.A., Williams, A.R., Anderson, R.A., and Jabbour, H.N. Expression, localization, and signaling of prostaglandin F2 alpha receptor in human endometrial adenocarcinoma: regulation of proliferation by activation of the epidermal growth factor receptor and mitogenactivated protein kinase signaling pathways. J. Clin. Endocrinol. Metab. 89:986-993, 2004.
97. Mao, W., Millar, J.C., Wang, W.H., Silverman, S.M., Liu, Y., Wordinger, R.J., Rubin, J.S., Pang, I.H., and Clark, A.F. Existence of the canonical Wnt signaling pathway in the human trabecular meshwork. Invest. Ophthalmol. Vis. Sci. 53:7043-7051, 2012.
98. Shyam, R., Shen, X., Yue, B.Y., and Wentz-Hunter, K.K. Wnt gene expression in human trabecular meshwork cells. Mol. Vis. 16:122-129, 2010.
99. Peng, J., Lei, C.T., Hu, J.B., and Fan, Y.C. Effects of travoprost on actin cytoskeleton and beta-catenin in the human trabecular meshwork cells treated with dexamethasone. Zhonghua Yan Ke Za Zhi. 47:336-341, 2011.
100. Kwon, H.S., and Tomarev, S.I. Myocilin, a glaucomaassociated protein, promotes cell migration through activation of integrin-focal adhesion kinase-serine/threonine kinase signaling pathway. J. Cell Physiol. 226:3392-3402, 2011.
101. Hutchinson, A.J., Coons, S.C., Chou, C.L., Xu, W., Stamer, W.D., Woodward, D.F., and Regan, J.W. Induction of angiogenic immediate early genes by activation of FP prostanoid receptors in cultured human ciliary smooth muscle cells. Curr. Eye Res. 35:408-418, 2010.
102. Liang, Y., Li, C., Guzman, V.M., Evinger 3rd, A.J., Protzman, C.E., Krauss, A.H., and Woodward, D.F. Comparison of prostaglandin F2alpha, bimatoprost (prostamide), and butaprost (EP2 agonist) on Cyr61 and connective tissue growth factor gene expression. J. Biol. Chem. 278:27267-27277, 2003.
103. Zhao, X., Pearson, K.E., Stephan, D.A., and Russell, P. Effects of prostaglandin analogues on human ciliary muscle and trabecular meshwork cells. Investig. Ophthalmol. Vis. Sci. 44:1945-1952, 2003.
104. Kass, M.A., Heuer, D.K., Higginbotham, E.J., Johnson, C.A., Keltner, J.L., Miller, J.P., Parrish 2nd, R.K., Wilson, M.R., and Gordon, M.O. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120:701-713, 2002; discussion 829-830.